Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 224 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Diuretics Clear all

Conditions: Hypertension
Interventions: Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Iowa City, Iowa • Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Heart Failure, Acute Heart Failure
Interventions: Protocolized diuretic therapy; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Prediabetic State
Interventions: Oral glucose tolerance test; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases
Interventions: Usual heart failure care, Interdisciplinary palliative care; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure Acute, Cardiovascular Diseases
Interventions: Metolazone Oral Tablet, Chlorothiazide Injection; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Chronic Kidney Disease, End Stage Renal Disease
Interventions: Metolazone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Unresectable Hepatocellular Carcinoma
Interventions: Hepatic artery embolization (HAE), Bumetanide; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more

Conditions: Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions: LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV); Other · Drug · Device
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more

Conditions: Ductus Arteriosus, Patent
Interventions: Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac; Device · Combination Product · Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 7 Days to 32 Days
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Heart Failure
Interventions: Spironolactone 100mg, Spironolactone 25mg; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Decompensated Heart Failure
Interventions: loop diuretic, tolvaptan, ultrafiltration; Drug · Procedure
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atrial Fibrillation
Interventions: Placebo, Ramipril, Spironolactone; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions: Blood Collection, Blood Volume Analysis; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Heart Failure
Interventions: adjustment of LVAD or pacemaker; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Eustachian Tube Dysfunction, Endolymphatic Hydrops
Interventions: Nasal steroid, Myringotomy tube placement, Diuretic, Antihistamine, Low salt diet; Drug · Procedure · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Nonmyeloablative allogeneic stem cell transplant; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Insufficiency, Congestive Heart Failure
Interventions: tonapofylline, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 68
States / cities: Huntsville, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 64 more

Conditions: Hypertension
Interventions: Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more

Conditions: Heart Failure
Interventions: Changes of heart failure medications; Drug
Lead sponsor: Alere San Diego; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Loma Linda, California • San Diego, California • Boston, Massachusetts + 3 more

Conditions: Hypertension
Interventions: Hydrochlorothiazide, Atenolol; Drug
Lead sponsor: University of Florida; Other
Eligibility: 17 Years to 65 Years
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota

Conditions: Ascites, Liver Cirrhosis
Interventions: Satavaptan, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Conditions: Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
Interventions: Indicor; Diagnostic Test
Lead sponsor: Vixiar Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Implementing Evidence Based Treatment of Hypertension

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

Palliative Care in Heart Failure

Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

Efficacy of Diuretics in Kidney Disease

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure

Study of the Wearable Defibrillator in Heart-Failure Patients

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

Prospective Observation of Exercise Parameters in Advanced Heart Failure

Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

HF Assessment With BNP in the Home: Part II

Pharmacogenomic Evaluation of Antihypertensive Responses

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Heart Failure Event Advance Detection Trial